Hiroyuki Koshio

689 citations

35 papers · 581 indexed · h-index 16

Hematology top 5%
Cardiology and Cardiovascular Medicine top 10%
Organic Chemistry top 10%
Molecular Biology
Genetics top 10%

Co-authors: Yuzo Matsumoto Tomihisa Kawasaki Fukushi Hirayama Kazuo Sato Yuta Taniuchi Takeyuki Yatsu Chiaki Kuroda Seiji Kaku
Topics: Blood Coagulation and Thrombosis Mechanisms (18 papers)Atrial Fibrillation Management and Outcomes (10 papers)Vitamin K Research Studies (6 papers)
Cited by: Hematology Internal Medicine Genetics
Journals: Blood Cancer Research Journal of Medicinal Chemistry
Partner nations: Japan Norway Netherlands

In The Last Decade

Hiroyuki Koshio

35 papers receiving 498 citations

Peers

Countries citing papers authored by Hiroyuki Koshio

Since Specialization

Citations

This map shows the geographic impact of Hiroyuki Koshio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroyuki Koshio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroyuki Koshio more than expected).

Fields of papers citing papers by Hiroyuki Koshio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroyuki Koshio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroyuki Koshio. The network helps show where Hiroyuki Koshio may publish in the future.

Co-authorship network of co-authors of Hiroyuki Koshio

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroyuki Koshio. A scholar is included among the top collaborators of Hiroyuki Koshio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroyuki Koshio. Hiroyuki Koshio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression 2019 ·Molecular Cancer Therapeutics ·Hiroaki Tanaka,Hideki Sakagami,Naoki Kaneko,(unknown),Hiroko Yamamoto,(unknown),Masatoshi Yuri,(unknown),Masamichi Mori,Masahiro Takeuchi,Hiroyuki Koshio,Masaaki Hirano,Sadao Kuromitsu	15
2	Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma 2019 ·Leukemia Research ·(unknown),Naoki Kaneko,Hideki Sakagami,(unknown),Masashi Hiramoto,(unknown),Masamichi Mori,Hiroyuki Koshio,Masaaki Hirano,Masahiro Takeuchi	3
3	Discovery of N -[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a Potent and Orally Available Factor Xa Inhibitor 2011 ·Journal of Medicinal Chemistry ·Fukushi Hirayama,Hiroyuki Koshio,Tsukasa Ishihara,(unknown),Keizo Sugasawa,(unknown),Norio Seki,(unknown),Takeshi Shigenaga,Yoshiyuki Iwatsuki,Yumiko Moritani,Kenichi Mori,Takeshi Kadokura,Tomihisa Kawasaki,Yuzo Matsumoto,Shuichi Sakamoto,Shin‐ichi Tsukamoto	27
4	Optimization of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin V2 receptor agonists and discussion of their binding modes 2009 ·Bioorganic & Medicinal Chemistry ·(unknown),Hiroyuki Koshio,Masaya Orita,(unknown),(unknown),(unknown),(unknown),Takeyuki Yatsu,Shuichi Sakamoto,Shin‐ichi Tsukamoto	1
5	Synthesis and structure–activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists 2009 ·Bioorganic & Medicinal Chemistry ·(unknown),Hiroyuki Koshio,(unknown),(unknown),(unknown),(unknown),(unknown),Takeyuki Yatsu,Yoshiaki Shimada,Shuichi Sakamoto,Shin‐ichi Tsukamoto	12
6	Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V2 receptor agonists 2008 ·Bioorganic & Medicinal Chemistry ·(unknown),Hiroyuki Koshio,(unknown),(unknown),(unknown),Takeyuki Yatsu,(unknown),(unknown),(unknown),Shuichi Sakamoto,Shin‐ichi Tsukamoto	7
7	Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors 2007 ·Bioorganic & Medicinal Chemistry ·Tsukasa Ishihara,Norio Seki,Fukushi Hirayama,Masaya Orita,Hiroyuki Koshio,Yuta Taniuchi,(unknown),Yoshiyuki Iwatsuki,Seiji Kaku,Tomihisa Kawasaki,Yuzo Matsumoto,Shin‐ichi Tsukamoto	7
8	Comparison of YM150, an Oral, Direct Factor Xa Inhibitor, with Other Antithrombotic Agents in Rodent Venous and Arterial Thrombosis Models. 2007 ·Blood ·(unknown),Seiji Kaku,Toshiyuki Funatsu,Hiroyuki Koshio,Tsukasa Ishihara,Fukushi Hirayama,Tomihisa Kawasaki,Masao Sasamata	7
9	Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity 2004 ·Bioorganic & Medicinal Chemistry ·Hiroyuki Koshio,Fukushi Hirayama,Tsukasa Ishihara,Yuta Taniuchi,Kazuo Sato,(unknown),Seiji Kaku,Tomihisa Kawasaki,Yuzo Matsumoto,Shuichi Sakamoto,Shin‐ichi Tsukamoto	14
10	Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives 2004 ·Bioorganic & Medicinal Chemistry ·Hiroyuki Koshio,Fukushi Hirayama,Tsukasa Ishihara,Hiroyuki Kaizawa,Takeshi Shigenaga,Yuta Taniuchi,Kazuo Sato,Yumiko Moritani,Yoshiyuki Iwatsuki,(unknown),Seiji Kaku,Tomihisa Kawasaki,Yuzo Matsumoto,Shuichi Sakamoto,Shin‐ichi Tsukamoto	12
11	Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template 2003 ·Bioorganic & Medicinal Chemistry ·Fukushi Hirayama,Hiroyuki Koshio,Naoko Katayama,Tsukasa Ishihara,Hiroyuki Kaizawa,Yuta Taniuchi,Kazuo Sato,(unknown),Seiji Kaku,Hiroyuki Kurihara,Tomihisa Kawasaki,Yuzo Matsumoto,Shuichi Sakamoto,Shin‐ichi Tsukamoto	13
12	The Discovery of YM-60828: A Potent, Selective and Orally-Bioavailable Factor Xa Inhibitor 2002 ·Bioorganic & Medicinal Chemistry ·Fukushi Hirayama,Hiroyuki Koshio,Naoko Katayama,Hiroyuki Kurihara,Yuta Taniuchi,Kazuo Sato,(unknown),(unknown),Tomihisa Kawasaki,Yuzo Matsumoto,Isao Yanagisawa	31
13	Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-Bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates 2002 ·Bioorganic & Medicinal Chemistry ·Fukushi Hirayama,Hiroyuki Koshio,Tsukasa Ishihara,(unknown),(unknown),Hiroyuki Kaizawa,(unknown),Naoko Katayama,Hiroyuki Kurihara,Yuta Taniuchi,Kazuo Sato,(unknown),Seiji Kaku,Tomihisa Kawasaki,Yuzo Matsumoto,Shuichi Sakamoto,Shin‐ichi Tsukamoto	17
14	Nonpeptide Arginine Vasopressin Antagonists for Both V1A and V2 Receptors: Synthesis and Pharmacological Properties of 4'-(1,4,5,6-Tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanilide Derivatives and 4'-(5,6-Dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilide Derivatives. 2000 ·Chemical and Pharmaceutical Bulletin ·Akio Matsuhisa,Naoyuki Taniguchi,Hiroyuki Koshio,Takeyuki Yatsu,Akihiro Tanaka	27
15	Nonpeptide Arginine Vasopressin Antagonists for Both V1A and V2 Receptors: Synthesis and Pharmacological Properties of 2-Phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl)benzanilide Derivatives. 1998 ·Chemical and Pharmaceutical Bulletin ·Akira Matsuhisa,Hiroyuki Koshio,(unknown),Nobuaki Taniguchi,Takeyuki Yatsu,Akihiro Tanaka	30
16	Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs 1998 ·European Journal of Pharmacology ·Kazuo Sato,Tomihisa Kawasaki,(unknown),Yuta Taniuchi,Fukushi Hirayama,Hiroyuki Koshio,(unknown),Yuzo Matsumoto	22
17	Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time 1998 ·European Journal of Pharmacology ·Kazuo Sato,Seiji Kaku,Fukushi Hirayama,Hiroyuki Koshio,Yuzo Matsumoto,Tomihisa Kawasaki,(unknown)	22
18	Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats 1998 ·European Journal of Pharmacology ·Kazuo Sato,Yuta Taniuchi,Tomihisa Kawasaki,Fukushi Hirayama,Hiroyuki Koshio,Yuzo Matsumoto	29
19	YM-60828, a novel factor Xa inhibitor: Separation of its antithrombotic effects from its prolongation of bleeding time 1997 ·European Journal of Pharmacology ·Kazuo Sato,Tomihisa Kawasaki,(unknown),Fukushi Hirayama,Hiroyuki Koshio,Yuzo Matsumoto	48
20	Biological Activity of Analogues of YM022. Novel (3-Amino Substituted Phenyl)urea Derivatives of 1,4-Benzodiazepin-2-one as Gastrin/Cholecystokinin-B Receptor Antagonists. 1996 ·Chemical and Pharmaceutical Bulletin ·(unknown),Yoshinori Okamoto,Hiroyuki Koshio,Mitsuaki Ohta,Akito Nishida,Shinobu Akuzawa,Keiji Miyata,Toshiyasu Mase,Graeme Semple	4

About Hiroyuki Koshio

Hiroyuki Koshio is a scholar working on Hematology, Internal Medicine and Genetics, having authored 35 papers that have together received 581 indexed citations. Recurring topics across this work include Blood Coagulation and Thrombosis Mechanisms (18 papers), Atrial Fibrillation Management and Outcomes (10 papers) and Vitamin K Research Studies (6 papers). The work is most often cited by research in Hematology (261 citations), Internal Medicine (83 citations) and Genetics (106 citations). Hiroyuki Koshio has collaborated with scholars based in Japan, Norway and Netherlands. Frequent co-authors include Yuzo Matsumoto, Tomihisa Kawasaki, Fukushi Hirayama, Kazuo Sato, Yuta Taniuchi, Takeyuki Yatsu, Chiaki Kuroda, Seiji Kaku, Shin‐ichi Tsukamoto and Tsukasa Ishihara. Their work appears in journals such as Blood, Cancer Research and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact